Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sutent price (correction)

Executive Summary

Based on the wholesale acquisition cost of Sutent (sunitinib), which is $6,412.50 for a 30 count bottle of 50 mg capsules, the product's average monthly cost is $4,275. This prices Sutent at a slight discount to Bayer/Onyx' Nexavar (sorafenib) which carries a WAC of $4,333 for a one-month supply. In a previous story on the approval of Sutent, "The Pink Sheet" incorrectly identified the price of the product and incorrectly referred to the average wholesale price of Nexavar as the price to patients (1"The Pink Sheet" Jan. 30, 2006, p. 4)...

You may also be interested in...



Pfizer Oncologic Sutent Will Have Dosing, Slight Price Advantage Over Nexavar

Pfizer's newly approved oncologic Sutent will have a dosing advantage and will be priced at a slight discount compared to Bayer/Onyx' Nexavar

Robust Trial Transparency Strategy Boosts Patient Engagement

Most clinical trial sponsors view data disclosure as a mandate, maintaining regulatory compliance as a legal requirement. Study sponsors that realize the potential to repurpose this data, using a patient-first approach, turn transparency into a strategic advantage for engagement and recruitment efforts.

Medtronic’s Perfusion System Recall Is Fifth Class I In 2 Months

The Bio-Console 560 extracorporeal blood pumping console is being recalled over reports it could lose power during bypass surgery, which could lead to organ or neural dysfunction, blood clots, or even death.

UsernamePublicRestriction

Register

PS046843

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel